BCL2 and BCLxL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells

Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma

(2012) Joan A. Puig-Butillé et al.   EXPERIMENTAL DERMATOLOGY

Tyrosine-phosphorylated Caveolin-1 (Tyr-14) Increases Sensitivity to Paclitaxel by Inhibiting BCL2 and BCLxL Proteins via c-Jun N-terminal Kinase (JNK)

(2012) Ayesha N. Shajahan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Vemurafenib: the first drug approved for BRAF-mutant cancer

(2012) Gideon Bollag et al.   NATURE REVIEWS DRUG DISCOVERY

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

(2011) Hiroyuki Inuzuka et al.   NATURE

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Loss of Class III β-Tubulin Induced by Histone Deacetylation Is Associated with Chemosensitivity to Paclitaxel in Malignant Melanoma Cells

(2009) Kiyomi Akasaka et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY